MASTER DAPT OAC

Overview

Image

clinical_evidence_master_dapt_icon_magnifying_glass
Investigator-initiated
global randomized study
global randomized study

Image

clinical_evidence_master_dapt_icon_globe
4,579 patients,
140 hospital worldwide, 30 countries
140 hospital worldwide, 30 countries

Image

clinical_evidence_master_dapt_icon_stethoscope
All-comers trial in
HBR patients after PCI
HBR patients after PCI

Image

clinical_evidence_master_dapt_icon_microscope
Abbreviated vs prolonged
DAPT in patients treated with
 the Utltimaster™and Ultimaster™ Tansei™ DES
DAPT in patients
treated with the
Ultimaster™ and
Ultimaster™Tansei™
DES

Study Design

Image

clinical_evidence_master_dapt_oac_study_design_1844x1140.png

Primary Endpoint

  • Net adverse clinical events (NACE) defined as a composite of death from any cause, myocardial infarction, stroke or major bleeding.
  • Major adverse cardiac and cerebrovascular events (MACCE), defined as a composite of death from any cause, myocardial infarction, stroke or major bleeding.
  • Major or clinically relevant non-major bleeding (MCB), defined as BARC 2, 3 or 5 bleeding.

Result

NACE

OAC indication HR 0.83, 95% CI 0.60-1.15;
p=0.26 No OAC indication HR HR 1.01, 95% CI 0.77-1.33;
p=0.91 Pinteraction=0.28

Image

clinical_evidence_master_dapt_oac_nace_1844x1140

MACCE

OAC indication HR0.88, 95% CI 0.60-1.30;
p=0.53 No OAC indication HR 1.06, 95% CI 0.79-1.44;
p=0.67 Pinteraction=0.46

Image

clinical_evidence_master_dapt_oac_macce_1844x1140

Major or clinically relevant non-major bleeding

OAC indication HR 0.83, 95% CI 0.62-1.12; p=0.25
No OAC indication HR 0.55, 95% CI 0.41-0.74; p<0.001P
Pinteraction=0.06

Image

clinical_evidence_master_dapt_oac_mcb_1844x1140
MASTER DAPT study is sponsored by the European Cardiovascular Research Institute (ECRI, Rotterdam, The Netherlands) and supported with a restricted research grant by Terumo Europe.